The Neuroimaging Research Unit is an international research centre, part of the Institute of Experimental Neurology, operating since 20 years. This unit currently comprises a multidisciplinary team including neurologists, neuroscientists, post-Docs, bioengineers, PhD students, residents in neurology, technicians and data-managers. The mission is to foster state-of-the-art neuroimaging research to identify and understand the processes that are associated with central nervous system (CNS) changes in normal aging and damage in diseased individuals.
Using structural MRI (conventional and non-conventional MRI, such as diffusion tensor imaging), the Unit is able to quantify tissue damage of macroscopic lesions, normal appearing white matter, normal appearing gray matter, spinal cord and optic nerve. Moreover, it is possible to assess the brain reorganization leading either to recovery of neurological functions or to persistent disability.
Neuroimaging research Unit has contributed to develop diagnostic criteria for MS, which are used globally, and uses MRI techniques to assess the efficacy of therapies in daily practice and treatment trials. During these years, the Unit also contributed to the definition of guidelines for the acquisition and the analysis of MRI sequences in the framework of longitudinal multicentre studies, and the development of new imaging acquisition protocols.
Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol 2018;17(2):133-142.
Filippi M, Basaia S, Canu E, Imperiale F, Magnani G, Falautano M, Comi G, Falini A, Agosta F. Changes in functional and structural brain connectome along the Alzheimer's disease continuum. Mol Psychiatry Epub 2018 May 9.
Agosta F, Spinelli EG, Marjanovic IV, Stevic Z, Pagani E, Valsasina P, Salak-Djokic B, Jankovic M, Lavrnic D, Kostic VS, Filippi M. Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology 2018;90(8):e707-e716.
Filippi M, Basaia S, Canu E, Imperiale F, Meani A, Caso F, Magnani G, Falautano M, Comi G, Falini A, Agosta F. Brain network connectivity differs in early-onset neurodegenerative dementia. Neurology 2017;89(17):1764-1772.
Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F, on behalf of the MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15(3):292-303.
Filippi M, van den Heuvel MP, Fornito A, He Y, Hulshoff Pol HE, Agosta F, Comi G, Rocca MA. Assessment of brain system dysfunction through MRI-based connectomics. Lancet Neurol 2013;12(12):1189-1199.
Kostić VS, Agosta F, Pievani M, Stefanova E, Ječmenica-Lukić M, Scarale A, Špica V, Filippi M. Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology 2012;78(6):409-416.
Filippi M, Rocca MA, Barkhof F, Brueck W, Chen JT, Comi G, DeLuca G, De Stefano N, Erickson BJ, Evangelou N, Fazekas F, Geurts JJG, Lucchinetti C, Miller DH, Pelletier D, Popescu BFG, Lassmann H, for the Attendees of the Correlation between Pathological and MRI findings in MS workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11(4):349-360.
Filippi M, Wolinsky JS, Comi G and the CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2006 Mar;5(3):213-20.
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G, and the ETOMS Study Group. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9444):1489-1496.
Resident in Neurology
Milagros Hidalgo de la Cruz